Halozyme Therapeutics (HALO) Work In Process (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Work In Process of $35.0 million for Q1 2026, down 4.4% year-over-year from $36.7 million in Q1 2025, and up 13.32% quarter-over-quarter from $30.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Work In Process (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Work In Process for 16 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Work In Process fell 4.4% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $35.0 million (down 4.4% YoY), while the FY2025 annual figure was $30.9 million, up 2.49% from the prior year.
- Work In Process grew to $35.0 million in Q1 2026 per HALO's latest filing, from $30.9 million in the prior quarter.
- Across five years, Work In Process topped out at $56.2 million in Q3 2022 and bottomed at $6.3 million in Q1 2022.
- Historically, Work In Process has averaged $34.9 million across 5 years, with a median of $35.0 million in 2026.
- Annual changes were most pronounced in 2022 — Work In Process sank 67.43% — and 2023, when it soared 332.75%.
- Halozyme Therapeutics' Work In Process stood at $44.1 million in 2022, then slipped by 22.85% to $34.0 million in 2023, then fell by 11.33% to $30.2 million in 2024, then grew by 2.49% to $30.9 million in 2025, then advanced by 13.32% to $35.0 million in 2026.
- Business Quant data shows HALO's Work In Process at $35.0 million in Q1 2026, $30.9 million in Q4 2025, and $34.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.40 Mn |
| Mar 31, 2026 | 35.04 Mn |
| Dec 31, 2025 | 30.92 Mn |
| Sep 30, 2025 | 34.84 Mn |
| Jun 30, 2025 | 30.93 Mn |
| Mar 31, 2025 | 36.65 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Sep 30, 2024 | 14.89 Mn |
| Jun 30, 2024 | 36.69 Mn |
| Mar 31, 2024 | 43.61 Mn |
| Dec 31, 2023 | 34.03 Mn |
| Sep 30, 2023 | 37.57 Mn |
| Jun 30, 2023 | 50.34 Mn |
| Mar 31, 2023 | 27.40 Mn |
| Dec 31, 2022 | 44.10 Mn |
| Sep 30, 2022 | 56.25 Mn |
| Jun 30, 2022 | 44.17 Mn |
| Mar 31, 2022 | 6.33 Mn |
| Dec 31, 2021 | 17.45 Mn |
| Sep 30, 2021 | 21.72 Mn |